english Archives - 29 중 7 번째 페이지

Seoul Asan Medical Center Achieves World’s First 9000 Liver Transplants

Dr. Lee Seung-kyu (far right), Professor at Seoul Asan Medical Center, performing a liver transplant. [Photo=Seoul Asan Medical Center] Seoul Asan Medical Center has reached a historic milestone, becoming the…

2426w

2025-05-15

GC Biopharma Secures FDA Approval for All 6 U.S. Plasma Centers…Sets Stage for ALYGLO Growth

GC Biopharma Headquarters. [Photo=녹십자] GC Biopharma announced on the 14th that all six of its plasma centers in the United States have received approval from the U.S. Food and Drug…

Cheon Okhyeon

2025-05-14

Hugel posts record Q1 operating profit of KRW39 billion

Hugel, a global total medical aesthetics company, posted its highest-ever first-quarter performance, fueled by robust sales across all product lines. The company announced on May 8 that its consolidated revenue…

Cheon Okhyeon

2025-05-08

Samsung Bioepis Wins U.S. Injunction Case Over Stelara Biosimilar

Samsung Bioepis has cleared a key legal hurdle in the U.S. market for its autoimmune disease biosimilar Pyzchiva, following a court ruling that dismissed an injunction request by Johnson &…

Cheon Okhyeon

2025-04-30

SK Biopharm Targets KRW 700 Billion in Annual Sales on Strong Epilepsy Drug Growth

SK Biopharm has set its sights on surpassing KRW 700 billion (approximately $515 million) in annual sales this year, driven by strong growth of its epilepsy drug, cenobamate (U.S. brand…

Cheon Okhyeon

2025-04-29

Celltrion’s Yuflyma Gains FDA Interchangeability with Humira

Celltrion’s autoimmune disease treatment Yuflyma can now be used as an interchangeable substitute for Humira in the United States without a physician’s prescription. Celltrion announced on April 14 that the…

Cheon Okhyeon

2025-04-14

GSK Taps ABL Bio’s Brain-Shuttle Tech in $3B+ Deal

South Korea’s ABL Bio, a biotech company specializing in bispecific antibodies, has signed a major licensing agreement with global pharmaceutical giant GSK for its proprietary blood-brain barrier (BBB)-penetrating platform, Grabody-B,…

Won Jonghyuck

2025-04-07

Korea United Pharm Expands Beyond modified drugs to Obesity and Cancer Therapies

Korea United Pharm, widely known for its stronghold in incrementally modified drugs (IMDs), is gearing up for its next growth phase with high-margin therapies, including obesity treatments and anticancer drugs.…

Cheon Okhyeon

2025-04-01

Bukwang Pharmaceutical Pursues Structural Overhaul Through Rights Offering

Bukwang Pharmaceutical which returned to profitability last year, has launched a rights offering to push ahead with a major structural overhaul. The company aims to resolve long-standing issues such as…

Cheon Okhyeon

2025-03-31

Jeil Pharmaceutical Names Han Sang-cheol Co-CEO to Launch 3rd-Gen Leadership

Jeil Pharmaceutical has officially entered a third-generation management era with the appointment of Han Sang cheol as co-CEO. On March 25, Jeil Pharmaceutical announced that its board of directors had…

Cheon Okhyeon

2025-03-25